Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer
Shamir P. Chandarana MD, MSc
Division of Otolaryngology—Head and Neck Surgery, University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada
Search for more papers by this authorJulia S. Lee MS, MPH
Institute for Social Research, University of Michigan, Ann Arbor, Michigan
Search for more papers by this authorEric J. P. Chanowski MD, MPH
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorAssuntina G. Sacco MD
Department of Internal Medicine, Loyola University Medical Center, Maywood, Illinois
Search for more papers by this authorCarol R. Bradford MD, MS
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorGregory T. Wolf MD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorMark E. Prince MD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorJeffrey S. Moyer MD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorAvraham Eisbruch MD
Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, Michigan
Search for more papers by this authorFrancis P. Worden MD
Department of Internal Medicine—Hematology/Oncology, University of Michigan Health System, Ann Arbor, Michigan
Search for more papers by this authorThomas J. Giordano MD, PhD
Departments of Pathology and Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan
Search for more papers by this authorBhavna Kumar MS
Department of Otolaryngology—Head and Neck Surgery, The Ohio State University, Columbus, Ohio
Search for more papers by this authorKatrina G. Cordell DDS, MS
Department of Oral and Maxillofacial Pathology, Louisiana State University Health Sciences Center, New Orleans, Louisiana
Search for more papers by this authorThomas E. Carey PhD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorCorresponding Author
Douglas B. Chepeha MD, MSPH
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health System, 1904 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0312Search for more papers by this authorShamir P. Chandarana MD, MSc
Division of Otolaryngology—Head and Neck Surgery, University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada
Search for more papers by this authorJulia S. Lee MS, MPH
Institute for Social Research, University of Michigan, Ann Arbor, Michigan
Search for more papers by this authorEric J. P. Chanowski MD, MPH
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorAssuntina G. Sacco MD
Department of Internal Medicine, Loyola University Medical Center, Maywood, Illinois
Search for more papers by this authorCarol R. Bradford MD, MS
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorGregory T. Wolf MD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorMark E. Prince MD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorJeffrey S. Moyer MD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorAvraham Eisbruch MD
Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, Michigan
Search for more papers by this authorFrancis P. Worden MD
Department of Internal Medicine—Hematology/Oncology, University of Michigan Health System, Ann Arbor, Michigan
Search for more papers by this authorThomas J. Giordano MD, PhD
Departments of Pathology and Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan
Search for more papers by this authorBhavna Kumar MS
Department of Otolaryngology—Head and Neck Surgery, The Ohio State University, Columbus, Ohio
Search for more papers by this authorKatrina G. Cordell DDS, MS
Department of Oral and Maxillofacial Pathology, Louisiana State University Health Sciences Center, New Orleans, Louisiana
Search for more papers by this authorThomas E. Carey PhD
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Search for more papers by this authorCorresponding Author
Douglas B. Chepeha MD, MSPH
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health, System, Ann Arbor, Michigan
Department of Otolaryngology—Head and Neck Surgery, University of Michigan Health System, 1904 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0312Search for more papers by this authorAbstract
Background
The purpose of this study was to describe the relationship of p16 and epidermal growth factor receptor (EGFR) expression with survival in surgically treated patients who had oropharyngeal or oral cavity squamous cell carcinoma (SCC).
Methods
Tissue from 36 patients with oropharyngeal SCC and 49 patients with oral cavity SCC treated between 1997 and 2001 was imbedded and immunostained using a tissue microarray.
Results
The p16 was positive in 57% and 13% of patients with oropharyngeal SCC and oral cavity SCC, respectively. EGFR was positive in 60% and 63% of patients with oropharyngeal SCC and oral cavity SCC, respectively. In patients with oropharyngeal SCC, p16 expression was associated with improved disease-specific survival (DSS), overall survival (OS), and time to recurrence (TTR) (p < .01, < .01, and <.01, respectively). EGFR expression was associated with poorer DSS, OS, and TTR (p < .01, = .01, and < .01, respectively). For oropharyngeal SCC, when examining both p16 and EGFR expression as combined biomarkers, high p16 expression coupled with low EGFR expression was associated with improved DSS (p p16 = .01; p EGFR = .01). Patients with oral cavity SCC showed no association between biomarker and outcome.
Conclusions
For patients with oropharyngeal SCC, high p16 and low EGFR were associated with improved outcome, suggesting a predictive role in surgically treated patients. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
REFERENCES
- 1 Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15: 6758–6762.
- 2 Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128–3137.
- 3 Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731–1738.
- 4 Preuss SF, Weinell A, Molitor M, et al. Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma. Head Neck 2008; 30: 1318–1324.
- 5 Numico G, Russi EG, Colantonio I, et al. EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res 2010; 30: 671–676.
- 6 Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350–7356.
- 7 Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 3138–3146.
- 8 Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553–561.
- 9 Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709–720.
- 10 Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002; 8: 3187–3192.
- 11 Lassen P, Eriksen JG, Hamilton–Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992–1998.
- 12 Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.
- 13 Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170–4176.
- 14 Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 140: 228–234.
- 15 Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins DR, Haughey BH. Transoral laser microsurgery (TLM) +/− adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 2009; 119: 1709–1719.
- 16 Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011; 33: 1683–1694.
- 17 Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630–5636.
- 18 Ukpo OC, Pritchett CV, Lewis JE, Weaver AL, Smith DI, Moore EJ. Human papillomavirus-associated oropharyngeal squamous cell carcinomas: primary tumor burden and survival in surgical patients. Ann Otol Rhinol Laryngol 2009; 118: 368–373.
- 19 Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336–344.
- 20 Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772–1783.
- 21 Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873–1878.
- 22 Smid EJ, Stoter TR, Bloemena E, et al. The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 1323–1329.
- 23 Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666–2672.
- 24 Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010; 16: 1226–1235.
- 25 Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23: 5560–5567.
Citing Literature
